About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

NOMID Symptoms Helped By Arthritis Drug

by Medindia Content Team on August 11, 2006 at 10:28 AM
Font : A-A+

NOMID Symptoms Helped By Arthritis Drug

Neonatal-onset multisystem inflammatory disease (NOMID) is a rare condition that affects children as well as adults. A new study finds that a drug named anakinra could alleviate symptoms and bring down the inflammation associated with the disease. The study is published in the August 10 issue of the New England Journal of Medicine. It was undertaken by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Advertisement

NOMID, also known as chronic infantile neurologic cutaneous articular (CINCA) syndrome, is an inflammatory disorder that affects numerous organs and body systems, including the skin, joints, eyes and central nervous system. For most children, the first sign of the disease is a rash that develops within the first six weeks of life. Other problems, including fever, meningitis, joint damage, vision and hearing loss, and mental retardation, can follow. NOMID is one of a group of illnesses that NIAMS Clinical Director Daniel Kastner M.D., Ph.D. has designated autoinflammatory diseases, because of their seemingly unprovoked episodes of inflammation. Despite treatment to control the inflammation — including high-dose corticosteroids, disease-modifying antirheumatic drugs such as methotrexate, and nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen — the disease is progressive and often fatal. As many as 20 percent of children with NOMID don't survive to adulthood.

'This research shows the importance of studying rare but enormously instructive diseases, a unique strength of the NIH intramural science program,' says NIH Director Elias A. Zerhouni, M.D. 'This study provides new insights on fundamental mechanisms of inflammation. More importantly this new therapy will reduce the pain and suffering of these young patients allowing them to live a fuller life than previously possible.'
Advertisement

While the mechanism of NOMID is not completely understood, research in recent years has revealed mutations in a gene called CIAS1 in approximately 60 percent of patients with the disease. CIAS1 encodes cryopyrin, which belongs to a group of interacting proteins involved in regulating inflammation and programmed cell death, which plays a crucial role in ridding the body of cells that are no longer needed. The mutations, scientists have found, lead to an imbalance of a cytokine, or chemical messenger, called interleukin-1 (IL-1), which is believed to drive the inflammation that causes damage in patients with the disease.

Isolated case reports have suggested that anakinra might be effective in treating the rash and other symptoms of NOMID. Anakinra is a biologic agent, a medicine based on compounds that are made by living cells and used to stimulate or restore the ability of the immune system to fight disease and/or infection. It works by blocking the effects of IL-1beta (IL-1฿), and is approved for treating rheumatoid arthritis. Until the new NIAMS study, however, the agent had not been systematically assessed in a larger group of patients with NOMID, and its effect on the most devastating organ manifestations — including the central nervous system, the eyes and the ears — had not been investigated, says Raphaela Goldbach-Mansky, M.D., a rheumatologist and the study's lead author.

To determine the possible role of anakinra in treating NOMID, the researchers treated 18 NOMID patients (12 with identifiable CIAS1 mutations) ages 4 to 32 with daily doses of anakinra based on body weight. At one, three and six months they assessed the treatment's effectiveness.

All 18 of the patients, they found, had an immediate clinical response to anakinra. Rash and conjunctivitis (inflammation of the membrane lining the eyelids), both common in NOMID, disappeared within three days. By three months, laboratory measures of inflammation, including erythrocyte sedimentation rate, c-reactive protein and serum amyloid A protein (SAA), had improved, and by six months, 33 percent of the patients showed improved hearing and another half of the patients had no further hearing loss from baseline. Other confirmed benefits of treatment included disappearance or lessening of headaches, reduction of central nervous system lesions, ability to lower corticosteroid doses, and remission of inflammation in more than half of patients by month six. At month three, disease flared in 11 patients when they were withdrawn from anakinra as part of the study, but when anakinra was restarted, the disease quickly responded again. Daily injections would be required for any long-term treatment.

'This study demonstrates the efficacy of anakinra in improving major organ manifestations and helps confirm the role of IL-1beta (IL-1฿) in many features of the disease; most importantly, the central nervous system,' says Dr. Goldbach-Mansky.

Because NOMID is a rare disease (400 to 600 children in the United States), the study was necessarily small and lacked a control group, but the study was strengthened by the magnitude of the clinical response to the agent and the fact that the disease flared when anakinra was temporarily stopped, she says.

'NOMID is a devastating disease for which previously there was little understanding or effective treatment,' says NIAMS Director Stephen I. Katz, M.D., Ph.D. 'This study not only provides hope — in the way of an already-available agent — but it also provides a better understanding of the mechanism of the disease's damaging effects.'

Furthermore, notes Goldbach-Mansky, anakinra was safe in this clinical investigation. Unlike some other treatments used for NOMID, it caused no serious side effects in any of the patients during the study.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Cervical Cancer Awareness Month 2022
Ultra-Low-Fat Diet
Goji Berries May Protect Against Age-Related Vision Loss
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Osteoarthritis Oligoarthritis Spondylolisthesis Signature Drug Toxicity Knee Replacement Reactive Arthritis Arthritis Septic Arthritis Physiotherapy for Arthritis 
Recommended Reading
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Knee Replacement
Make sprinting a possibility! Relieve chronic arthritic pain by having a knee replacement done at ...
Oligoarthritis
Most parents when told that their child has arthritis find it hard to believe it, as arthritis is re...
Osteoarthritis
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a...
Physiotherapy for Arthritis
Physiotherapy enables patients with debilitating disease to regain loss of function in their muscles...
Reactive Arthritis
Reactive arthritis is an autoimmune condition. Ankylosing spondylitis, psoriatic arthritis are disor...
Septic Arthritis
Septic Arthritis or Infectious Arthritis is infection of a joint due to bacteria or other organisms....
Spondylolisthesis
Spondylolisthesis is a condition of the lower spine in which one of the bones of the vertebral colum...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)